- Home
- DUK vs BMY Comparison
DUK vs BMY Comparison
Compare DUK & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUK
- BMY
- Stock Information
- Founded
- DUK 1904
- BMY 1887
- Country
- DUK United States
- BMY United States
- Employees
- DUK N/A
- BMY N/A
- Industry
- DUK Railroads
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- DUK Industrials
- BMY Health Care
- Exchange
- DUK Nasdaq
- BMY Nasdaq
- Market Cap
- DUK 89.7B
- BMY 97.6B
- IPO Year
- DUK N/A
- BMY N/A
- Fundamental
- Price
- DUK $118.73
- BMY $47.49
- Analyst Decision
- DUK Buy
- BMY Hold
- Analyst Count
- DUK 17
- BMY 16
- Target Price
- DUK $127.67
- BMY $58.33
- AVG Volume (30 Days)
- DUK 2.8M
- BMY 14.4M
- Earning Date
- DUK 08-05-2025
- BMY 07-31-2025
- Dividend Yield
- DUK 3.52%
- BMY 5.22%
- EPS Growth
- DUK 51.35
- BMY N/A
- EPS
- DUK 6.02
- BMY 2.67
- Revenue
- DUK $30,512,000,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- DUK $7.08
- BMY N/A
- Revenue Next Year
- DUK $3.65
- BMY N/A
- P/E Ratio
- DUK $19.75
- BMY $17.79
- Revenue Growth
- DUK 5.22
- BMY 4.62
- 52 Week Low
- DUK $99.21
- BMY $39.35
- 52 Week High
- DUK $125.27
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- DUK 58.10
- BMY 39.49
- Support Level
- DUK $115.35
- BMY $46.32
- Resistance Level
- DUK $117.96
- BMY $47.07
- Average True Range (ATR)
- DUK 1.57
- BMY 0.79
- MACD
- DUK 0.35
- BMY -0.16
- Stochastic Oscillator
- DUK 85.70
- BMY 6.21
About DUK Duke Energy Corporation (Holding Company)
Duke Energy is one of the largest US utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to more than 8 million customers. Its natural gas utilities serve more than 1.6 million customers.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.